Literature DB >> 25771413

Accelerated repopulation as a cause of radiation treatment failure in non-small cell lung cancer: review of current data and future clinical strategies.

Sue S Yom1.   

Abstract

Despite convincing evidence that the principles of accelerated repopulation would open up additional therapeutic opportunities in the treatment of advanced-stage non-small cell lung cancer, this strategy has been generally underexplored. The implementation of accelerated radiotherapy schedules has been hampered by logistical barriers, concerns about acute toxicity, and the prioritization of integrating concurrent chemotherapy into the standard treatment platform. At present, it is unclear to what extent accelerated fractionation will influence future treatment paradigms in non-small cell lung cancer, although technical advances in radiotherapy, allowing higher dose delivery with reduced toxicity, could permit the development of more convenient and tolerable forms of accelerated schedules.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25771413     DOI: 10.1016/j.semradonc.2014.12.002

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  13 in total

1.  Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Authors:  Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-04-01       Impact factor: 6.223

Review 2.  Radiobiology of stereotactic body radiation therapy (SBRT).

Authors:  Miquel Macià I Garau
Journal:  Rep Pract Oncol Radiother       Date:  2017-03-23

3.  Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.

Authors:  Jenny Ling-Yu Chen; Jo-Pai Chen; Yu-Sen Huang; Yuan-Chun Tsai; Ming-Hsien Tsai; Fu-Shan Jaw; Jason Chia-Hsien Cheng; Sung-Hsin Kuo; Ming-Jium Shieh
Journal:  Strahlenther Onkol       Date:  2016-03-07       Impact factor: 3.621

4.  Properties and gene expression profiling of acquired radioresistance in mouse breast cancer cells.

Authors:  Feng Qin; Qiang Fan; Peter K N Yu; Waleed Abdelbagi Almahi; Peizhong Kong; Miaomiao Yang; Wei Cao; Lili Nie; Guodong Chen; Wei Han
Journal:  Ann Transl Med       Date:  2021-04

Review 5.  Ion Transport and Radioresistance.

Authors:  Bastian Roth; Stephan M Huber
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

6.  Emergent properties of a computational model of tumour growth.

Authors:  Pan Pantziarka
Journal:  PeerJ       Date:  2016-06-29       Impact factor: 2.984

7.  MicroRNA-124 regulates the radiosensitivity of non-small cell lung cancer cells by targeting TXNRD1.

Authors:  Chuncheng Hao; Xiangying Xu; Jia Ma; Jun Xia; Bingbing Dai; Lili Liu; Yuyan Ma
Journal:  Oncol Lett       Date:  2017-02-08       Impact factor: 2.967

8.  MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma.

Authors:  Cory Pettit; Amy Webb; Steve Walston; Moumita Chatterjee; Wei Chen; Wendy Frankel; Carlo Croce; Terence M Williams
Journal:  Oncotarget       Date:  2018-06-22

9.  Chemotherapy induces ovarian cancer cell repopulation through the caspase 3-mediated arachidonic acid metabolic pathway.

Authors:  Lianzhi Cui; Yawei Zhao; Yue Pan; Xiao Zheng; Dan Shao; Yong Jia; Kan He; Kun Li; Li Chen
Journal:  Onco Targets Ther       Date:  2017-12-08       Impact factor: 4.147

10.  Timing of thoracic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer: a parallel comparison of two prospective studies.

Authors:  Xiao Hu; Bing Xia; Yong Bao; Yu-Jin Xu; Jin Wang; Hong-Lian Ma; Fang Peng; Ying Jin; Min Fang; Hua-Rong Tang; Meng-Yuan Chen; Bai-Qiang Dong; Jia-Nan Jin; Xiao-Long Fu; Ming Chen
Journal:  Strahlenther Onkol       Date:  2019-11-29       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.